Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Fosun International Limited
  6. News
  7. Summary
    656   HK0656038673


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

How Pfizer vaccine could be cold comfort for some Asian nations

11/10/2020 | 06:32am EDT
FILE PHOTO: A woman holds a small bottle labeled with a

TOKYO/SEOUL/MANILA (Reuters) - With tropical heat, remote island communities and a dearth of ultra-cold freezers, many Asian countries aren't betting on Pfizer's experimental vaccine solving their COVID-19 crisis any time soon.

The world cheered on Monday when Pfizer Inc announced its shot, jointly developed with BioNTech SE, was more than 90% effective based on initial trial results.

Yet health experts cautioned that the vaccine, should it be approved, was no silver bullet - not least because the genetic material it's made from needs to be stored at temperatures of minus 70 degrees Celsius (-94 F) or below.

Such requirements pose a particularly daunting challenge for countries in Asia, as well as in places like Africa and Latin America, where intense heat is often compounded by poor infrastructure that will make it difficult to keep the "cold chain" intact during deliveries to rural areas and islands.

That is a problem for everyone in the world, given the World Health Organization estimates about 70% of people must be inoculated to end the pandemic, and Asia alone is home to more than 4.6 billion - or three-fifths of the global population.

Some Asian countries are prioritising containing the novel coronavirus rather than looking to stockpile vaccines, while others are looking for alternatives to the messenger RNA technology used by Pfizer that requires such ultra-cold storage.

"On the cold chain requirement of -70 degrees, that is a hefty requirement. We do not have such facility," Philippines' Health Secretary Francisco Duque told Reuters.

"We will have to wait and see for now," he added. "The technology Pfizer is using is new technology. We don't have experience with that, so risks can be high."

Pfizer told Reuters that it had developed detailed logistical plans and tools to support vaccine transport, storage and continuous temperature monitoring.

"We have also developed packaging and storage innovations to be fit for purpose for the range of locations where we believe vaccinations will take place," it said.


Yet even wealthier nations like South Korea and Japan are managing expectations.

"Storage is going to be a big challenge for us," said Fumie Sakamoto, infection control manager at St. Luke's International Hospital in Tokyo.

"I'm not sure how well prepared our government is with regards to maintaining the cold chain. Hospitals in Japan usually do not have ultra-cold freezers, but I think it's high time we started thinking about the logistics for the vaccine."

Japan is among three countries in Asia Pacific that have announced supply deals for the Pfizer/BioNTech vaccine. It has signed a deal for 120 million doses, while Australia has secured 10 million doses and China's Fosun has secured 10 million doses for Hong Kong and Macau.

Japan's PHC Corp, which supplies medical freezers, told Reuters that demand had shot up 150% this year and that they were increasing production to meet demand.

Kwon Jun-wook, an official at South Korea's Disease Control and Prevention Agency (KDCA), said it wanted to see how vaccination progressed in other countries first and would thoroughly review its supply chain.

The country had recently experienced the problems of cold storage when it had to discard about 5 million doses of flu vaccines because they were not stored at recommended temperatures.

A 2018 study commissioned by the agency found that only a quarter of 2,200 private clinics it surveyed had medical refrigerators, with 40% using household refrigerators.

For some countries, it's still very early days.

Indonesia, whose 273 million people are scattered over more than 17,000 islands, is considering a variety of vaccines, but the Pfizer one is not yet among them, said Airlangga Hartarto, who heads the country's COVID-19 response team.

Vietnam, which successfully contained its outbreak through aggressive mass testing and strict border controls, said it would continue to focus on containment effort.

"The vaccine is a story for the future," Deputy Prime Minister Vu Duc Dam, told a government meeting on Friday.

"Demand is far higher than supply, and we have to pay large deposits to secure our position, which I see as very high risk and a waste of money and time."

(Reporting by Sangmi Cha in Seoul, Rocky Swift in Tokyo, Neil Jerome Morales in Manila and Gayatri Suroyo in Jakarta; Writing by Miyoung Kim; Editing by Pravin Char)

By Rocky Swift, Sangmi Cha and Neil Jerome Morales

ę Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE 3.41% 351.81 Delayed Quote.331.56%
DOW JONES AFRICA TITANS 50 INDEX -0.01% 526.59 Delayed Quote.-0.45%
FOSUN INTERNATIONAL LIMITED 1.35% 10.52 End-of-day quote.-13.63%
PANASONIC CORPORATION -0.15% 1336 End-of-day quote.12.22%
PFIZER, INC. 3.91% 45.68 Delayed Quote.24.10%
S&P AFRICA 40 INDEX 0.35% 171.59 Delayed Quote.-1.16%
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. 5.24% 86.71 End-of-day quote.60.60%
SILVER 0.36% 25.632 Delayed Quote.-3.60%
07/19Sisram Medical Seeks $80 Million in Private Placement; Shares Fall 6%
07/13Hong Kong says no personal data shared in vaccine deal with Fosun
07/12Politics, health collided in Taiwan's tortured BioNTech vaccine talks
07/11Taiwan finally getting BioNTech COVID vaccines in $350 mln deal
07/06Fosun International Limited commences an Equity Buyback for 836,590,642 share..
06/11VIEWRAY : Insider Sales at ViewRay (VRAY) are Significant
06/10MARKET CHATTER : Juneyao Airlines, Trip.com Seen Bidding for HNA Assets
06/10INSIDER TRENDS : Insider Adds to Selling Trend at ViewRay
06/09SHANGHAI FOSUN PHARMACEUTICAL : Fosun, CQ Pharma Enter Into Mutual Supply Agreem..
06/09Shanghai Fosun Pharmaceutical Co., Ltd. Enter into Fosun International Mutual..
More news
Sales 2021 153 B 23 671 M 23 671 M
Net income 2021 13 090 M 2 023 M 2 023 M
Net Debt 2021 111 B 17 119 M 17 119 M
P/E ratio 2021 5,43x
Yield 2021 3,95%
Capitalization 73 252 M 11 320 M 11 321 M
EV / Sales 2021 1,20x
EV / Sales 2022 1,12x
Nbr of Employees 76 000
Free-Float 27,7%
Duration : Period :
Fosun International Limited Technical Analysis Chart | 656 | HK0656038673 | MarketScreener
Technical analysis trends FOSUN INTERNATIONAL LIMITED
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 9
Last Close Price 8,75 CNY
Average target price 10,98 CNY
Spread / Average Target 25,4%
EPS Revisions
Managers and Directors
Qi Yu Chen Co-Chief Executive Officer & Executive Director
Xiao Liang Xu Co-Chief Executive Officer & Executive Director
Ping Gong Chief Financial Officer & Executive Director
Hou Lin Zhang Co-Chief Financial Officer & Senior Vice President
Li Gang Zhang Co-CFO & GM-Financial Management
Sector and Competitors
1st jan.Capi. (M$)
ALLIANZ SE-3.49%94 858
CHUBB LIMITED10.67%74 739